文献速递艾滋病与性传播感染

治疗前HIV耐药对死亡率、脱失和病毒抑制的影响及传播网络:中国西南观察性队列研究

Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

该研究在中国西南开展2014–2022年观察性队列,纳入3478例启动抗逆转录病毒治疗(ART)的患者,分析治疗前耐药(PDR)对死亡率、脱失和病毒抑制的影响。PDR总患病率为6.4%,PDR与脱失风险增加和病毒抑制率降低显著相关,尤其对依非韦伦/奈韦拉平耐药者,但与死亡率无显著关联。

要点

  • PDR总患病率6.4%,NNRTI耐药率4.1%最常见。
  • PDR与脱失风险增加相关,总体调整HR 1.67(95%CI 1.11–2.52)。
  • PDR组病毒抑制显著降低,AOR 0.46(95%CI 0.27–0.77)。

核心结论

  • 中国西南地区PDR患病率中等,与脱失和病毒学失败风险增加显著相关。
  • 依非韦伦/奈韦拉平耐药者脱失和病毒抑制不良风险尤为突出。
  • 研究支持在启动ART前常规进行PDR检测以指导优化一线治疗方案。

研究设计与样本

  • 2014–2022年在中国西南开展观察性队列研究。
  • 共纳入3478例符合条件、启动ART的患者。
  • 使用Stanford HIV Drug Resistance Database分析PDR,用HIV-TRACE构建分子传播网络。
  • 采用Cox和logistic回归评估PDR对结局的影响。

主要发现

  • 总体PDR患病率为6.4%;NNRTI、NRTI和PI耐药率分别为4.1%、1.3%和1.1%。
  • 总体死亡率为4.58/100人年,脱失率为2.40/100人年。
  • PDR与死亡率无显著关联,但与脱失风险增加相关:总体耐药组调整HR 1.67(95%CI 1.11–2.52),NNRTI耐药组2.16(95%CI 1.36–3.43),依非韦伦/奈韦拉平耐药组2.09(95%CI 1.10–3.97)。
  • 病毒抑制在耐药组显著降低:总体耐药组AOR 0.46(95%CI 0.27–0.77),NNRTI耐药组AOR 0.42(95%CI 0.22–0.78),依非韦伦/奈韦拉平耐药组AOR 0.41(95%CI 0.21–0.81)。

临床怎么用

  • 对启动ART的患者,尤其存在NNRTI或依非韦伦/奈韦拉平耐药风险者,应考虑治疗前PDR检测。
  • 根据PDR结果选择优化的一线ART方案,以降低脱失和病毒学失败风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pretreatment drug resistance (PDR) compromises antiretroviral therapy (ART) efficacy and is a major concern in HIV care, yet its consequences for key treatment outcomes are not well-defined. We therefore systematically investigated the prevalence of PDR and its impact on mortality, attrition and viral suppression amongst patients starting ART. METHODS: An observational cohort study was conducted in Southwest China, 2014-2022. PDR was analysed using the Stanford HIV Drug Resistance Database. Molecular transmission networks were constructed with HIV-TRACE. Cox and logistic regression evaluated the impact of PDR. RESULTS: Amongst 3478 eligible patients, the overall prevalence of PDR was 6.4%. PDR rates to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors and protease inhibitors were 4.1%, 1.3% and 1.1%, respectively. The overall mortality and attrition rates were 4.58 and 2.40 per 100 person-years, respectively. Whilst PDR showed no significant association with mortality, it was associated with increased attrition. Compared to those without resistance, the adjusted HR (95% CI) for attrition was 1.67 (1.11-2.52) in the overall drug-resistant group, 2.16 (1.36-3.43) in the NNRTI-resistant group and 2.09 (1.10-3.97) in the efavirenz/nevirapine-resistant group. Viral suppression was significantly lower in the drug-resistant group [adjusted odds ratio (AOR): 0.46; 95% CI: 0.27-0.77], the NNRTI-resistant group (AOR: 0.42; 95% CI: 0.22-0.78) and the efavirenz/nevirapine-resistant group (AOR: 0.41; 95% CI: 0.21-0.81). CONCLUSIONS: Our study reveals a moderate prevalence of PDR in Southwest China, significantly associated with increased risk of attrition and virologic failure, particularly amongst patients with resistance to efavirenz/nevirapine. Our findings strongly advocate for routine PDR testing prior to ART initiation to guide optimal first-line treatment strategies.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Qin L, Xie Y, Li J, et al. Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China. J Antimicrob Chemother. 2026. PMID: 41770585. doi:10.1093/jac/dkag073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。